Phase 2b results – Citius Pharmaceuticals (Mino-Lok®)

Phase 3 Study

Based on Phase 2b results, Citius Pharmaceuticals believes that our Mino-Lok® product is highly effective in salvaging infected indwelling catheters and is well-tolerated, making Mino-Lok therapy an attractive alternative to removing and replacing a new CVC.

Study Objectives

Citius is conducting a Phase 3, multi-center, randomized, open-label, assessor-blinded study with about 700 patients. The objectives of the study are the following:

  • To evaluate the efficacy of Mino-Lok along with standard of care (SOC) systemic antibiotics for salvaging the central venous catheter (CVC) in subjects with catheter-related or central line-associated bloodstream infection (CRBSI/CLABSI)
  • To evaluate the safety of Mino-Lok in subjects with CRBSI/CLABSI.